Drew Pardoll News Today : Breaking News, Live Updates & Top Stories | Vimarsana

<p>Drugs that target a receptor on immune cells called activin receptor 1C may combat tumor-induced immune suppression and help patients&rsquo; immune systems fight back against cancer, according to a study by investigators at the <a href="https://www.hopkinsmedicine.org/kimmel-cancer-center">Johns Hopkins Kimmel Cancer Center</a> and its&nbsp;<a href="https://www.hopkinsmedicine.org/kimmel-cancer-center/bloomberg-kimmel-institute-for-cancer-immunotherapy">Bloomberg~Kimmel Institute for Cancer Immunotherapy</a><u>.</u></p...

As AI and new imaging tools give researchers vast amounts of data on tumors, they are winning some battles against this complex disease.

Treating cancer with immunotherapies known as an immune checkpoint blockade (ICB) prior to surgery (so-called neoadjuvant immunotherapy) has been a rapidly growing area of research, but the scientific community is just scratching the surface of what is possible, according to a review article co-authored by several current and former investigators from the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins Kimmel Cancer Center.

Johns Hopkins Medicine scientists say they have developed a nanoparticle -; an extremely tiny biodegradable container -; that has the potential to improve the delivery of messenger ribonucleic acid (mRNA)-based vaccines for infectious diseases such as COVID-19, and vaccines for treating non-infectious diseases including cancer.

Johns Hopkins Medicine scientists say they have developed a nanoparticle — an extremely tiny biodegradable container — that has the potential to improve the delivery of messenger ribonucleic acid (mRNA)-based vaccines for infectious diseases such as COVID-19, and vaccines for treating non-infectious diseases including cancer.